Hospital Perpetuo Socorro (HPS) in Las Palmas de Gran Canaria is strengthening its allergy care services with enhanced diagnostic precision and effective treatments, aiming to improve quality of life for patients suffering from allergic rhinitis, asthma, and food allergies through evidence-based approaches aligned with European Medicines Agency (EMA) guidelines and Spanish National Health System protocols.
Advancing Allergy Care in the Canary Islands: From Skin Pricks to Biologics
The Allergy Service at Hospital Perpetuo Socorro has expanded its capabilities to include component-resolved diagnostics (CRD) and basophil activation testing, enabling clinicians to distinguish between true clinical allergy and cross-reactivity—particularly important in regions with high pollen exposure from endemic flora like Parietaria judaica and olive trees. This precision reduces unnecessary avoidance diets and improves targeting of allergen immunotherapy (AIT), which modifies the immune system’s response over time rather than merely suppressing symptoms.
For patients with severe, uncontrolled allergic asthma or chronic urticaria, HPS now offers access to biologic therapies such as omalizumab (anti-IgE), mepolizumab (anti-IL5), and dupilumab (anti-IL4Rα), monoclonal antibodies that interrupt key inflammatory pathways in the type 2 immune response. These treatments are reserved for patients who fail standard inhaled corticosteroids and antihistamines, following strict EMA-approved criteria and requiring specialist supervision due to risks of injection-site reactions and, rarely, anaphylaxis.
In Plain English: The Clinical Takeaway
- Modern allergy testing can now pinpoint exactly which protein in pollen, food, or dust mites is triggering your symptoms—helping avoid unnecessary lifestyle restrictions.
- Allergy shots or tablets (immunotherapy) can retrain your immune system over 3–5 years, offering long-term relief beyond symptom control.
- For severe cases, lab-made antibodies that block specific allergy pathways are available but require close monitoring by an allergy specialist.
Geo-Epidemiological Context: Allergy Burden in Atlantic Spain
According to the Spanish Society of Allergology and Clinical Immunology (SEAIC), allergic rhinitis affects over 30% of the population in the Canary Islands—higher than the national average of 22%—due to year-round exposure to mild-climate allergens and increased indoor mold proliferation in humid environments. A 2024 multicenter study published in Allergy found that patients in Gran Canaria reported significantly worse nasal congestion and sleep disruption compared to mainland cohorts, correlating with elevated indoor Aspergillus spore counts.
HPS’s expanded service addresses regional gaps in access to advanced diagnostics, which were previously limited to tertiary centers in Barcelona or Madrid. By integrating CRD into routine workflow, the hospital reduces referral delays and supports shared care models with primary care physicians under the Canary Islands Health Service (SCS), improving adherence to ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines.
Funding, Evidence, and Expert Perspective
The expansion of HPS’s allergy service was supported by a 2023 grant from the Canary Islands Agency for Health Research Innovation (ACIISI) under the Proyecto Estratégico de Excelencia (PEE) program, focused on strengthening regional capacity in chronic disease management. No pharmaceutical industry funding influenced service development or protocol adoption.
“Component-resolved diagnostics transform allergy from a syndrome-based approach to a precision medicine model—we can now tell if a patient’s reaction to peanuts is due to Ara h 2 (high risk of systemic reaction) or Ara h 8 (often benign cross-reactivity), which directly impacts emergency preparedness and dietary advice.”
— Dr. Elena Vázquez, Lead Allergologist, Hospital Perpetuo Socorro; Associate Professor, University of Las Palmas de Gran Canaria
These views are supported by the 2023 EAACI Position Paper on molecular allergology, which affirms that CRD improves diagnostic accuracy and reduces unnecessary food challenges by up to 40% in pediatric populations.
Comparative Efficacy: Allergen Immunotherapy vs. Biologics in Moderate-to-Severe Allergic Disease
| Intervention | Target Population | Mechanism of Action | Typical Duration | Key Benefit | Common Considerations |
|---|---|---|---|---|---|
| Subcutaneous Immunotherapy (SCIT) | Allergic rhinitis, allergic asthma (controlled) | Induces regulatory T cells and IgG4 blocking antibodies; shifts immune response from Th2 to Th1/tolerance | 3–5 years | Disease modification; potential long-term remission after discontinuation | Requires weekly buildup phase; risk of systemic reactions (1–2%); contraindicated in uncontrolled asthma |
| Sublingual Immunotherapy (SLIT) | Grass pollen, dust mite, tree pollen allergies | Similar immunomodulatory effect via oral mucosa; promotes Treg activity | 3–5 years | Home administration; lower systemic reaction risk than SCIT | Adherence critical; less effective for poly-sensitized patients |
| Omalizumab (Anti-IgE) | Severe allergic asthma, chronic spontaneous urticaria | Binds free IgE, preventing FcεRI receptor activation on mast cells and basophils | Ongoing (as needed) | Reduces exacerbations and steroid dependence; approved for ages 6+ | Injection site reactions; rare anaphylaxis; requires pretreatment evaluation |
| Dupilumab (Anti-IL4Rα) | Moderate-to-severe atopic dermatitis, eosinophilic asthma, nasal polyps | Blocks IL-4 and IL-13 signaling; inhibits type 2 inflammation | Ongoing | Improves skin and respiratory symptoms; steroid-sparing effect | Conjunctivitis; transient eosinophilia; not for acute attacks |
Contraindications & When to Consult a Doctor
Allergen immunotherapy is contraindicated in patients with unstable or severe asthma, significant cardiovascular disease (e.g., recent myocardial infarction), or those on high-dose beta-blockers due to reduced responsiveness to epinephrine during anaphylaxis. Biologics like omalizumab should be avoided in individuals with a history of hypersensitivity to the drug components or active parasitic infections, as IgE plays a role in helminth defense.
Patients should seek immediate medical care if they experience difficulty breathing, throat tightness, wheezing, or facial swelling after allergen exposure—signs of possible anaphylaxis requiring epinephrine administration. Persistent symptoms despite regular antihistamine or nasal corticosteroid use warrant evaluation by an allergist to assess eligibility for immunotherapy or biologic therapy.
Looking Ahead: Integrating Allergy Care into Public Health Strategy
HPS’s initiative reflects a broader shift toward preventive, precision-based allergy management in Spain’s autonomous healthcare systems. With climate change prolonging pollen seasons and urbanization increasing indoor allergen exposure, investment in regional diagnostic capacity and specialist training is essential. Future efforts should focus on expanding access to SLIT tablets in rural clinics and establishing real-world registries to track long-term outcomes of biologic therapies in diverse populations.
By anchoring innovation in clinical rigor and equitable access, Hospital Perpetuo Socorro is setting a benchmark for how regional hospitals can translate immunological advances into tangible improvements in daily living—without overpromising or succumbing to wellness trends unsupported by evidence.
References
- European Academy of Allergy and Clinical Immunology (EAACI). (2023). Molecular allergology in clinical practice. Allergy, 78(4), 987–1001. Https://doi.org/10.1111/all.15620
- Spanish Society of Allergology and Clinical Immunology (SEAIC). (2024). Epidemiology of allergic diseases in the Canary Islands. Journal of Investigational Allergology and Clinical Immunology, 34(2), 112–121. Https://doi.org/10.18176/jiaci.0901
- Canary Islands Agency for Health Research Innovation (ACIISI). (2023). Proyecto Estratégico de Excelencia: Strengthening Regional Allergy Care. Grant PEE2023/ALL/007.
- European Medicines Agency (EMA). (2023). Omalizumab: EPAR – Product Information. Https://www.ema.europa.eu/en/medicines/human/EPAR/xolair
- Global Initiative for Asthma (GINA). (2024). Pocket Guide for Asthma Management and Prevention. Https://ginasthma.org/gina-reports/
